Palbociclib, a selective CDK4/6 inhibitor, has demonstrated promising efficacy in preclinical HCC models and is being evaluated as a novel therapeutic option in clinical trials. Additionally, CDK4/6 inhibition induces cellular senescence, potentially influencing the tumor microenvironment and immunogenicity...
The increased and earlier use of CDK4/6 inhibitors has resulted in a better understanding of the mechanisms of acquired resistance; potential treatment combinations that might overcome these mechanisms are being explored. Treatment selection after disease progression on a CDK4/6 inhibitor remains an ar...
There are 2 main areas we’re evaluating for patients whose cancers are progressing on initial endocrine therapy plus a CDK4/6 inhibitor. One is to investigate new targeted agents that might target the biology of the cancer more effectively....
Molecular pathways:targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin Cancer Res 2015,21(13):2905-2910.[3] Lawrence M.; Gelbert.; Shufen Cai.; Xi Lin .; and et al. Preclinical characterizationof the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independentanti-...
Frauen mit fortgeschrittenem Hormonrezeptor(HR)-positivem, HER2-negativem Brustkrebs leben signifikant länger, wenn sie mit einem CDK4/6-Inhibitor in Kombination mit einer endokrinen Therapie behandelt werden, als mit einer endokrinen Therapie allein. Das ergab die Zwischenauswertung der Studie...
[3] Lawrence M.; Gelbert.; Shufen Cai.; Xi Lin .; and et al. Preclinical characterizationof the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independentanti-tumor activities alone/in combination with gemcitabine.Invest Ne...
were treated with the CDK4/6 inhibitor PD-0332991, a potent cytostatic agent that is in phase II clinical trials or multiple malignancies, including breast cancer. 11-13 Treatment with PD-0332991 revealed highly pro ound suppression o Ki67 stain- ...
Fig. 2 Distribution of AE of CDK4/6 inhibitorin different systemic organs NPT represented the number of PTs that generate a signal under the ROR combined with MHRA method; ROR025...
infopharm Fortgeschrittenes Mammakarzinom CDK4/6-Inhibitor besonders effektiv Mit der EU-Zulassung von Palbociclib steht der erste CDK4/6-Inhibitor für Patientinnen mit lokal fortgeschrittenem bzw. metastasiertem HR- positivem/HER2-negativem Brustkrebs zur Verfügung. Die Zulassung gilt für ...
近日,辉瑞公司研究团队在 Cell 子刊 Cancer Cell 上发表了题为:Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor 的研究论文。 该研究通过临床前模型和临床标本的转录组分析发现了PAL耐药的机制,使用合成的小分子药物PF3600靶向细胞周期蛋白依赖性激酶CDK2、CDK4和CDK6可以克服对CDK4/6抑制...